PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer

Cancer Research

Volumn 77, Issue 22, 2017, Pages 6353-6364

  Kansy, Benjamin A ^a,b   Concha Benavente, Fernando ^a   Srivastava, Raghvendra M ^a   Jie, Hyun Bae ^a   Shayan, Gulidanna ^c   Lei, Yu ^d   Moskovitz, Jessica ^a   Moy, Jennifer ^a   Li, Jing ^c   Brandau, Sven ^b   Lang, Stephan ^b   Schmitt, Nicole C ^e,f   Freeman, Gordon J ^g   Gooding, William E ^h   Clump, David A ^a   Ferris, Robert L ^a,h  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Tsinghua University   (China)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR MONOCLONAL ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; PDCD1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FLOW CYTOMETRY; GENE FREQUENCY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, INBRED C57BL; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROPORTIONAL HAZARDS MODELS;

EID: 85033795095     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-3167     Document Type: Article

References (47)

1. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 2015:0.
2. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009;206: 1717–25.
3. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Eng J Med 2015;373:123–35.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med 2015;373:23–34.
5. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015;33:2013–20.
6. Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol 2014;50: 565–74.
7. Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–67.
8. Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, et al. Identification of the cell-intrinsic and extrinsic pathways downstream of EGFR and IFNg that induce PD-L1 expression in head and neck cancer. Cancer Res 2016;76:1031–43.
9. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33:3293–304.
10. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Nat Acad Sci USA 2008;105:15016–21.
11. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(þ) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014;124:2246–59.
12. Badoual C, Hans S, Merillon N, Van Ryswick C Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128–38.
13. Li J, Shayan G, Avery L, Jie H-B, Gildener-Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: evidence for intracellular cross talk. Oncoimmunology 2016; in press.
14. Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology 2017;6: e1261779.
15. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415:536–41.
16. Anderson AC, Lord GM, Dardalhon V, Lee DH, Sabatos-Peyton CA, Glimcher LH, et al. T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol 2010;40:859–66.
17. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol 2015;6:418.
18. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT:Co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016;44:989–1004.
19. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8þ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117:3383–92.
20. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. inhibitory receptor expression depends more dominantly on differentiation and activation than "Exhaustion" of human CD8 T cells. Front Immunol 2013;4:455.
21. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576–82.
22. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011; 12:323.
23. Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol–Head Neck Surg 2007;133:495–502.
24. Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009;15:1623–34.
25. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J clin Invest 2014;124:687–95.
26. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curropinion Immunol 2005;17:326–32.
27. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8þ T cell exhaustion during chronic viral infection. Immunity 2007;27:670–84.
28. Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, et al. PD-1/ SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015;75:508–18.
29. Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109: 2629–35.
30. Maxwell JH, Ferris RL, Gooding W, Cunningham D, Mehta V, Kim S, et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 2013;119:3302–8.
31. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 2012;366:2443–54.
32. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, et al. Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. J Immunol 2015;194:950–9.
33. Ferris R. PD-1 targeting in cancer immunotherapy. Cancer 2013;119:E1–3.
34. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432–3.
35. Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, et al. PD-1-mediated suppression of IL-2 production induces CD8þ T cell anergy in vivo. J Immunol 2009;182:6682–9.
36. Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine 2015;94:e515.
37. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Eng J Med 2010;363:24–35.
38. Rosales R, Rosales C. Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol 2014;5:1002–19.
39. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733–41.
40. Morales-Sanchez A, Fuentes-Panana EM. Human viruses and cancer. Viruses 2014;6:4047–79.
41. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(þ) T cells induced by melanoma vaccines. Cancer Res 2014;74:1045–55.
42. Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8þ T-cell responses in hepatocellular carcinoma. Hepatol-ogy 2014;59:1415–26.
43. Zhang G, Li Z, Han Q, Li N, Zhu Q, Li F, et al. Altered TNF-alpha and IFN-gamma levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection. Infect Genet Evol 2011;11:1624–30.
44. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012;72:5209–18.
45. Blackburn SD, Crawford A, Shin H, Polley A, Freeman GJ, Wherry EJ. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol 2010; 84:2078–89.
46. Tanguy Y. Seiwert BB, Weiss J, Gluck I, Eder JP, Pai SI, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. J Clin Oncol 2014 ASCO Annual Meeting Abstracts 2014;Vol 32.
47. Fury SIO M, Balmanoukian AS, Hansen A, Massarelli E, Blake-Haskins A, Li X, et al. 988PD - Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in patients with head and neck cancer. Ann Oncol 2014;25: iv340–iv56.